GeneDx (NASDAQ:WGS) shares maintained their ground following a reiteration of a Hold rating and a $75.00 price target by Jefferies analysts. According to InvestingPro data, analyst targets for the ...

Wells Fargo notes that shares of GeneDx (WGS) are trading lower after a short report was published this morning by Grizzly Research, adding ...

TD Cowen analyst Daniel Brennan maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today and set a price target of $118.00. The ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

Learn more about whether Clover Health Investments, Corp. or GeneDx Holdings Corp. is a better investment based on AAII's A+ ...

GAITHERSBURG, Md., January 28, 2025--GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025 STAMFORD, Conn., January 17, 2025--GeneDx Holdings Corp ...

GeneDx (WGS) Holdings eported preliminary financial results for the fourth quarter and full year of 2024. “2024 was a transformative year for GeneDx, as we achieved our profitability milestone ...

Learn more about whether The Ensign Group, Inc. or GeneDx Holdings Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and ...

“2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengthened our products and expanded our team to set ...